N. Benslimane, C. Loret, P. Chazelas, F. Favreau, P.A. Faye, F. Lejeune and A.S. Lia. (2024). Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons. Pharmaceuticals 17 (314). https://doi.org/10.3390/ph17030314 (IF: 5.2).

J. Carrard and F. Lejeune. (2023). Nonsense-mediated mRNA decay, a simplified view of a complex mechanism. BMB reports 56(12):625-632. Invited review. doi: 10.5483/BMBRep.2023-0190 (IF : 3.8).

J. Carrard, F. Ratajczak, J. Elsens, C. Leroy, R. Kong, L. Geoffroy, A. Comte, G. Fournet, B. Joseph, X. Li, S. Moebs-Sanchez and F. Lejeune. (2023). Identifying Potent Nonsense- Mediated mRNA Decay Inhibitors with a Novel Screening System. Biomedicines - https://doi.org/10.3390/biomedicines11102801 (IF: 4.7).

N. Benslimane, F. Miressi, C. Loret, L. Richard, A. Nizou, I. Pyromali, PA. Faye, F. Favreau, F. Lejeune and AS. Lia. (2023). Amlexanox: Readthrough Induction and Nonsense- Mediated mRNA Decay Inhibition in a Charcot–Marie–Tooth Model of hiPSCs-Derived Neuronal Cells Harboring a Nonsense Mutation in GDAP1 Gene. Pharmaceuticals (IF: 5.2)

C. Leroy, S. Spelier, N.C. Essonghe, V. Poix, R. Kong, P. Gizzi, C. Bourban, S. Amand, C. Bailly, R. Guilbert, D. Hannebique, P. Persoons, G. Arhant, A. Prévotat, P. Reix, D. Hubert, M. Gérardin, M. Chamaillard, N. Prevarskaya, S. Rebuffat, G. Shapovalov, J. Beekman and F. Lejeune. (2023). Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis. Molecular Therapy  (IF: 12.91)

F. Lejeune. (2022). Nonsense-Mediated mRNA Decay, a Finely Regulated Mechanism. Biomedecines 10(1): 141 (IF: 6.0)

M. Palma, C. Leroy, S. Salomé-Desnoulez, E. Werkmeister, R. Kong, M. Mongy, H. Le Hir and F. Lejeune. (2021). A role for AKT1 in nonsense-mediated mRNA decay. Nucleic Acid Research 49(19):11022-11037 (IF: 16.97)

M. Palma and F. Lejeune. (2021). Deciphering the molecular mechanism of stop codon readthrough. Biol Rev Camb Philos Soc: doi: 10.1111/brv.12657 (IF: 12.82)

C. Trzaska, S. Amand, C. Bailly. C. Leroy, V. Marchand, E. Duvernois-Berthet, JM. Saliou, H. Benhabiles, E. Werkmeister, T. Chassat, R. Guilbert, D. Hannebique, A. Mouray, MC. Copin, PA. Moreau, E. Adriaenssens, A. Kulozik, E. Westhof, D. Tulasne, Y. Motorin, S. Rebuffat and F. Lejeune. (2020). 2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations. Nature Com. 11(1):1509. (IF: 14.919)

A. Bokhari, V. Jonchere, A. Lagrange, R. Bertrand, M. Svrcek, L. Marisa, O. Buhard, M. Greene, A. Demidova, J. Jia, E. Adriaenssens, T. Chassat, D.S. Biard, J.F. Flejou, F. Lejeune, A. Duval, A. Collura (2018). Targeting nonsense-mediated mRNA decay in colorectal cancers with microsatellite instability. Oncogenesis 7:70. (IF : 5.9)

H. Benhabiles, S. Gonzalez-Hilarion, S. Amand, C. Bailly, A. Prévotat, P. Reix, D. Hubert, E. Adriaenssens, S. Rebuffat, D. Tulasne and F. Lejeune. (2017). Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases. Plos One 12: e0187930. (IF: 2.7)

F. Lejeune. Nonsense-mediated mRNA decay at the crossroads of many cellular pathways. (2017). BMB Rep. 50:175-185.  Invited Review (IF: 3.1)

J. Jia, S. Gonzalez-Hilarion, E. Werkmeister, F. Lafont, D.C. Grunert, D. Tulasne and F. Lejeune. (2017). PTC readthrough in human cells occurs in novel cytoplasmic foci and requires UPF proteins. J. Cell Sci. 130:3009-3022. (IF: 4.5)

F. Lejeune. (2016). Triple effect of nonsense-mediated mRNA decay inhibition as a therapeutic approach for cancer. Single Cell Biology. 5:136. Invited Review

H. Benhabiles, J. Jia and F. Lejeune. (2016). Nonsense mutation correction in human diseases, an approach for targeted medicine. Ed. Elsevier Book: 1-192.

J. Jia, A. Furlan, S. Gonzalez-Hilarion, C. Leroy, D.C. Gruenert, D. Tulasne and F. Lejeune. (2015). Caspases shut down nonsense-mediated mRNA decay during apoptosis. Cell Death and Differentiation. 22:1754-1763. (IF: 10.7)

S. Gonzalez-Hilarion, T. Beghyn, N. Debreuck, K. Mamchaoui, V. Mouly, D.C. Gruenert, B. Deprez and F. Lejeune. (2012). Rescue of nonsense mutations by amlexanox in human cells. Orphanet Journal of rare Diseases 7:58. (IF: 5.7)

S. Apcher, C. Daskalogianni, F. Lejeune, B. Manoury, G. Imhoos, L. Heslop and R. Fahraeus (2011). Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. PNAS 108:11572-11577. (IF: 10.7)

N. Dreumont, C.F. Bourgeois, F. Lejeune, Y. Liu, D.J. Elliot and J. Stévenin (2010). Human RBMY regulates germline-specific splicing events by modulation the function of serine-arginine rich proteins 9G8 and Tra2beta. J. Cell Sci. 123:40-50. (IF: 4.5)

S. Durand, N. Cougot, F. Mahuteau-Betzer, CH. Nguyens, D. Grierson, E. Bertrand, J. Tazi, F. Lejeune (2007). Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J Cell Biol. 178:1145-1160. (IF: 8.8)